Halaven Dailymed
Generic: eribulin mesylate is used for the treatment of Breast Neoplasms Liposarcoma
Go PRO for all pill images
Halaven
(eribulin mesylate) Injection, for intravenous use 1Â mg/2Â mL (0.5Â mg/mL)
Principal Display Panel - Shipper Label
Eisai Manufacturing Limited               Â
​Allegato DQA-035/XXXX​
New Chemical Entity Demand Chain Unit European Knowledge Centre
Mosquito Way-Hatfield, Herts, AL 109SN
United Kingdom
​​ HALAVEN® (eribulin mesylate) Injection, for intravenous use- 0.5mg/ml, 2 ml Store at 15° - 25°C (59° - 77°F). DO NOT FREEZE
QTY: 00XXX EXP: MM-YYYY LOT: F1XXYZZZ Â (22) 900XXX MMYYYY F1XXYZZZ 7
NDC 43624-002-01
(0X) 50X XXXXX 00X X X0 XXX
Manufactured by : BSP Pharmaceuticals SpA-Latina Scalo, Italy.
​
DISCLAIMER:
"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."
"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."
"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."
PillSync may earn a commission via links on our site
